The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Pfizer CEO ‘disappointed’ by Robert Kennedy’s refusal to rebut claims on vaccine risks
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
BioSpace1d
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
Pfizer’s Albert Bourla on Trump 2.0: ‘The status quo will collapse’
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...